Guided Therapeutics Reports Revenue Growth and Increased Net Loss in Q3 2025

Guided Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a significant increase in revenue compared to the same period last year. The company generated $60,000 in sales from its LuViva devices and disposables during the three months ended September 30, 2025, a notable rise from zero revenue in the prior-year quarter. For the nine months ending September 30, 2025, total revenue reached $177,000, compared to $6,000 in the same period of 2024. The cost of goods sold for the quarter was $25,000, leading to a gross profit of $35,000.

Despite the increase in revenue, Guided Therapeutics reported a net loss of $785,000 for the third quarter of 2025, compared to a net loss of $692,000 in the same quarter of 2024. The nine-month net loss attributable to common stockholders was $2.1 million, up from $1.9 million in the previous year. The company’s operating expenses totaled $520,000 for the quarter, with research and development expenses accounting for $136,000, reflecting a 22% increase from the prior year. General and administrative expenses were $362,000, slightly lower than the previous year's $374,000.

In terms of operational developments, Guided Therapeutics has made strides in its clinical trials for the LuViva device, surpassing the minimum enrollment target of 400 participants. The company is also pursuing regulatory approvals in multiple markets, including the U.S. and China. However, it faced challenges with its Chinese partner, SMI, which defaulted on contractual obligations, leading to the loss of rights to market LuViva in China. The company is now in discussions with a new partner to continue commercialization efforts in that region.

As of September 30, 2025, Guided Therapeutics had total assets of $903,000, down from $1.4 million at the end of 2024. The company reported current liabilities of $6.5 million, resulting in a stockholders' deficit of approximately $5.6 million. The company’s cash reserves decreased to $87,000, down from $388,000 at the end of 2024. The company indicated that it would need to continue raising capital to support its operations and FDA approval processes, with a projected need of approximately $2.3 million over the next 12 months.

Looking ahead, Guided Therapeutics remains focused on completing its FDA study and obtaining necessary regulatory approvals. The company has also initiated a private placement offering, which has already raised approximately $200,000, to bolster its financial position. However, the company cautioned that without sufficient capital, it may need to curtail operations and reduce spending, which could impact its ability to continue its product development and commercialization efforts.